84年鼠女哪年财运最旺,857comvvv色九欧美激情|85PO_87国产精品欲av国产av资源

[1]黃小龍,全仁夫,胡華輝,等.HLA-B2704基因型強直性脊柱炎患者來源的人誘導多能干細胞體系的建立[J].中醫(yī)正骨,2017,29(12):11-18.
　HUANG Xiaolong,QUAN Renfu,HU Huahui,et al.Establishment of human-induced pluripotent stem cells system originated from patients with HLA-B2704 genotypic ankylosing spondylitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(12):11-18.
點擊復制

HLA-B2704基因型強直性脊柱炎患者來源的人誘導多能干細胞體系的建立()
分享到：

《中醫(yī)正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第29卷
期數:
2017年12期
頁碼:
11-18
欄目:
基礎研究
出版日期:
2017-12-20

文章信息/Info

Title:
Establishment of human-induced pluripotent stem cells system originated from patients with HLA-B2704 genotypic ankylosing spondylitis
作者:
黃小龍1; 全仁夫1; 胡華輝1; 李偉1; 李強1; 邱銳2; 孫亞萍3; 楊迪生4
1.浙江省杭州市蕭山區(qū)中醫(yī)院,浙江 杭州 311201; 2.浙江中醫(yī)藥大學,浙江 杭州 310053; 3.浙江大學,浙江 杭州 310058; 4.浙江大學附屬第二醫(yī)院,浙江 杭州 310009
Author(s):
HUANG Xiaolong1; QUAN Renfu1; HU Huahui1; LI Wei1; LI Qiang1; QIU Rui2; SUN Yaping3; YANG Disheng4
1.Xiaoshan Hospital of Chinese Medicine,Hangzhou 311201,Zhejiang,China 2.Zhejiang Chinese Medical University,Hangzhou 310053,Zhejiang,China 3.Zhejiang University,Hangzhou 310058,Zhejiang,China 4.The Second Affiliated Hospital of Zhejiang University,Hangzhou 310009,Zhejiang,China
關鍵詞:
脊柱炎; 強直性;  HLA抗原;  尿;  誘導多能干細胞
Keywords:
Key words spondylitis; ankylosing;  HLA antigens;  urine;  induced pluripotent stem cells
摘要:
目的:建立人類白細胞抗原(human leukocyte antigen,HLA)-B2704基因型強直性脊柱炎(ankylosing spondylitis,AS)患者來源的人誘導多能干細胞(human-induced pluripotent stem cells,hiPSCs)體系。方法:采用逆轉錄病毒介導的感染系統(tǒng)把OCT4、SOX2、c-MYC、KLF4這4個外源轉錄因子導入HLA-B2704基因型AS患者的尿液細胞中,重編程獲得hiPSCs。通過形態(tài)觀察、堿性磷酸酶染色、免疫熒光染色、內源多能性相關基因檢測、體外擬胚體(embryoid bodies,EBs)分化檢測、EBs三胚層基因檢測以及畸胎瘤形成實驗,鑒定獲得的hiPSCs。結果:病毒感染尿液細胞后第4天至第5天細胞核質比增大,第14天左右出現克隆,第24天后形成與人胚胎干細胞(human embryonic stem cells,hESCs)相似的克隆。堿性磷酸酶染色顯示,hiPSCs和hESCs-H1一樣,均被染成紫紅色,呈陽性。免疫熒光染色顯示,hESCs階段特異性胚胎抗原4及ESCs轉錄因子OCT4、SOX2均呈陽性。hiPSCs內源多能性基因OCT4、SOX2、NANOG和REX1的表達與H1內源多能性相關基因的表達比較,差異均無統(tǒng)計學意義(1.006±0.208,1.000±0.340,t=0.038,P=0.972; 1.061±0.140,1.000±0.387,t=0.431,P=0.689; 1.386±0.354,1.000±0.032,t=1.467,P=0.303; 1.280±0.283,1.000±0.013,t=1.398,P=0.235)。EBs高表達內胚層基因AFP、GATA4,中胚層基因MEX1、TBX1,外胚層基因PAX6、SOX1; EBs三胚層基因AFP、GATA4、TBX1、MSX1、PAX6、SOX1的相對表達量均高于hiPSCs(60.695±8.746,1.000±0.245,t=9.647,P=0.011; 3.724±0.144,1.000±0.417,t=12.136,P=0.007; 4.224±0.869,1.000±0.130,t=4.988,P=0.038; 684.800±63.326,1.000±0.211,t=15.270,P=0.004; 131.561±15.785,1.000±0.232,t=11.700,P=0.007; 98.507±40.443,1.000±0.215,t=16.000,P=0.004)。hiPSC體內形成畸胎瘤,HE染色可見內、中、外3個胚層的組織細胞; 其中內胚層為小腸上皮組織細胞,中胚層為肌肉組織細胞,外胚層為神經上皮組織細胞。結論:采用逆轉錄病毒介導的感染系統(tǒng)把OCT4、SOX2、c-MYC、KLF4這4個外源轉錄因子導入HLA-B2704基因型AS患者的尿液細胞中,經過重編程,可成功建立HLA-B2704基因型AS患者來源hiPSCs體系。
Abstract:
ABSTRACT Objective:To establish the human-induced pluripotent stem cells(hiPSCs)system originated from patients with human leukocyte antigen(HLA)-B2704 genotypic ankylosing spondylitis(AS).Methods:Four exogenous transcription factors including OCT4,SOX2,c-MYC and KLF4 were introduced into the urinary cells(UCs)of patients with HLA-B2704 genotypic AS by using retrovirus-mediated infection system,and the infected UCs were reprogrammed for obtaining hiPSCs.The hiPSCs were identified through morphologic observation,alkaline phosphatase staining,immunofluorescence staining,endogenous multipotent related gene detection,embryoid bodies(EBs)differentiation detection,EBs triploblastic gene detection and teratoma formation experiment.Results:The nuclear-cytoplasmic ratioincreased at the 4th and 5th day after UCs were infected by virus.The clone appeared at the 14th day and it was similar to human embryonic stem cells(hESCs)at the 24th day.The result of alkaline phosphatase staining showed that both hiPSCs and hESCs-H1 were presented with prunosus positive staining.The result of immunofluorescent staining showed that the stage specific embryonic antigen 4(SSEA4)of hESCs and the transcription factor of ESCs including OCT4 and SOX2 presented with positive staining.There was no statistical difference in the expression of endogenous multipotent related gene including OCT4,SOX2,NANOG and REX1 between hiPSCs and hiPSCs-H1(1.006+/-0.208 vs 1.000+/-0.340,t=0.038,P=0.972; 1.061+/-0.140 vs 1.000+/-0.387,t=0.431,P=0.689; 1.386+/-0.354,1.000+/-0.032,t=1.467,P=0.303; 1.280+/-0.283 vs 1.000+/-0.013,t=1.398,P=0.235).High expressions of endodermal genes including AFP and GATA4,mesodermal genes including MEX1 and TBX1 and ectodermal genes including PAX6 and SOX1 were found in EBs.The relative expression levels of triploblastic genes including AFP,GATA4,TBX1,MSX1,PAX6 and SOX1 were higher in EBs compared to hiPSCs(60.695+/-8.746 vs 1.000+/-0.245,t=9.647,P=0.011; 3.724+/-0.144 vs 1.000+/-0.417,t=12.136,P=0.007; 4.224+/-0.869 vs 1.000+/-0.130,t=4.988,P=0.038; 684.800+/-63.326 vs 1.000+/-0.211,t=15.270,P=0.004; 131.561+/-15.785 vs 1.000+/-0.232,t=11.700,P=0.007; 98.507+/-40.443 vs 1.000+/-0.215,t=16.000,P=0.004).Teratoma appeared in hiPSC.Small intestine epithelial histocytes,muscular histocytes and neuroepithelial histocytes were found respectively in entoderm,mesoderm and ectoderm of teratoma through HE staining.Conclusion:The hiPSCs system originated from patients with HLA-B2704 genotypic AS can be successfully established through introducing four exogenous transcription factors including OCT4,SOX2,c-MYC and KLF4 into UCs of patients with HLA-B2704 genotypic AS by using retrovirus-mediated infection system and reprogramming the UCs.

參考文獻/References:

[1] SIEPER J,BRAUN J,KAY J,et al.Sarilumab for the treatment of ankylosing spondylitis:results of a Phase Ⅱ,randomised,double-blind,placebo-controlled study(ALIGN)[J].Ann Rheum Dis,2015,74(6):1051-1057.
[2] OMAIR MA,ALDURAIBI FK,BEDAIWI MK,et al.Prevalence of HLA-B27 in the general population and in patients with axial spondyloarthritis in Saudi Arabia[J].Clinical Rheumatology,2017,36(7):1537-1543.
[3] 白世杰,托婭,張寶平,等.強制性脊柱炎及其相關基因HLA-B27檢驗的研究現狀[J].分子診斷與治療雜志,2016,8(3):2016-210.
[4] KOUI Y,KIDO T,ITO T,et al.An in vitro human liver model by iPSC-Derived parenchymal and non-parenchymal cells[J].Stem Cell Reports,2017,9(2):490-498.
[5] MARCATILI M,MARSONER F,D'AGOSTINO AA,et al.Establishment of an induced pluripotent stem cell(iPSC)line from a patient with Clozapine-responder Schizophrenia[J].Stem Cell Res,2016,17(3):630-633.
[6] BROWN MA,KENNA T,WORDSWORTH BP.Genetics of ankylosing spondylitis-insights into pathogenesis[J].Nat Rev Rheumatol,2016,12(2):81-91.
[7] TAM LS,GU J,YU D.Pathogenesis of ankylosing spondylitis[J].Nat Rev Rheumatol,2010,6(7):399-405.
[8] BROWN MA,LAVAL SH,BROPHY S,et al.Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis[J].Ann Rheum Dis,2000,59(11):883-886.
[9] KRAGSTRUP TW,ANDERSEN MN,SCHITTZCHRISTENSEN B,et al.Increased IL-20 and IL-24 target osteoblasts and synovial monocytes in spondyloarthritis[J].Clin Exp Immunol,2017,189(3):342-351.
[10] TAKEUCHI M,OMBRELLO MJ,KIRINO Y,et al.A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Behcet's disease in HLA-B(star)51 carriers[J].Ann Rheum Dis,2016,75(12):2208-2211.
[11] CHEN C,ZHANG X,WANG Y.Analysis of JAK2 and STAT3 polymorphisms in patients with ankylosing spondylitis in Chinese Han population[J].Clinical Immunology,2010,136(3):442-446.
[12] AKKOC N,YARKAN H,KENAR G.Ankylosing spondylitis:HLA-B*27-positive versus HLA-B*27-negative disease[J].Curr Rheumatol Rep,2017,19(5):322-328.
[13] TAKAHASHI K,TANABE K,OHNUKI M,et al.Induction of pluripotent stem cells from adult human fibroblasts by defined factors[J].Cell,2007,131(5):861-872.
[14] YU JY,VODYANIK MA,SMUGA-OTTO KA,et al.Induced pluripotent stem cell lines derived from human somatic cells[J].Science,2007,318(5858):1917-1920.
[15] AASEN T,RAYA A,BARRERO MJ,et al.Efficient and rapid Generation of induced pluripotent stem cells from human keratinocytes[J].Nat Biotechnol,2008,26(11):1276-1284.
[16] STADTFELD M,NAGAYA M,UTIKAL J,et al.Induced pluripotent stem cells generated without viral integration[J].Science,2008,322(593):945-949.
[17] HWANG GH,PARK SM,HAN HJ,et al.Purification of small molecule-induced cardiomyocytes from human induced pluripotent stem cells using a reporter system[J].J Cell Physiol,2017,232(12):3384-3395.
[18] SHI Y,DO JT,DESPONTS C,et al.A combined chemical and genetic approach for the Generation of induced pluripotent stem cells[J].Cell Stem Cell,2008,2(6):525-528.
[19] LIAO J,WU Z,WANG Y,et al.Enhanced efficiency of generating induced pluripotent stem(iPS)cells from human somatic cells by a combination of six transcription factors[J].Cell Res,2008,18(5):600-603.
[20] ZHOU T,BENDA C,DUNZINGER S,et al.Generation of human induced pluripotent stem cells from urine samples[J].Nat Protoc,2012,7(12):2080-2089.

相似文獻/References:

[1]閻曉霞,任之強,仝允輝,等.布魯氏菌性脊柱炎3例[J].中醫(yī)正骨,2015,27(06):64.
[2]趙偉光,劉振武,劉利,等.強直性脊柱炎合并右側股骨頭和股骨頸骨溶解癥1例[J].中醫(yī)正骨,2015,27(01):75.
[3]黃建武,黃建華,黃影.腫瘤壞死因子-α在強直性脊柱炎活動期患者中的表達[J].中醫(yī)正骨,2013,25(11):22.
[4]張董喆,孔超,張建福.針刺夾脊穴結合督灸治療強直性脊柱炎[J].中醫(yī)正骨,2014,26(07):58.
[5]吳建國.強直性脊柱炎并發(fā)脊柱骨折的影像學表現[J].中醫(yī)正骨,2013,25(06):31.
[6]謝國華,薛峰,楊建平,等.強直性脊柱炎脊柱應力性骨折的診斷[J].中醫(yī)正骨,2012,24(12):72.
[7]張萬義,張永紅,王笑青.雙醋瑞因膠囊聯合柳氮磺胺吡啶腸溶片與右旋布洛芬膠囊治療強直性脊柱炎[J].中醫(yī)正骨,2012,24(06):26.
　ZHANG Wan-yi*,ZHANG Yong-hong,WANG Xiao-qing.*.Study on the curative effects of diacerein capsules combined with sulfasalazine enteric-coated tablets and dextral ibuprofen capsules in the treatment of ankylosing spondylitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(12):26.
[8]黃建華,黃建武,陳金春,等.早期強直性脊柱炎血管內皮生長因子、C反應蛋白 表達水平的臨床研究[J].中醫(yī)正骨,2012,24(02):9.
　HUANG Jian-hua*,HUANG Jian-wu,CHEN Jin-chun,et al.Clinical research on the expression of VEGF、CRP in early ankylosing spondylitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(12):9.
[9]王笑青,張永紅,王玉麗,等.常規(guī)藥物口服配合中藥離子導入治療強直性脊柱炎肌腱附著點炎[J].中醫(yī)正骨,2011,23(10):18.
　WANG Xiao-qing*,ZHANG Yong-hong,WANG Yu-li,et al.A study on the curative effects of oral conventional drugs combined with traditional Chinese medicine iontophoresis on ankylosing spondylitis tendon enthesitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2011,23(12):18.
[10]劉紅軍.單節(jié)段楔形截骨結合椎弓根A-F系統(tǒng)內固定 治療強直性脊柱炎脊柱后凸畸形[J].中醫(yī)正骨,2011,23(09):65.
[11]戴霞華,李寅潔.指導性功能鍛煉在兒童強直性脊柱炎護理中的應用[J].中醫(yī)正骨,2015,27(10):78.
[12]張夢雨,鮑鐵周,田江波.督脈隔姜灸聯合柳氮磺吡啶腸溶片口服及 功能鍛煉治療強直性脊柱炎[J].中醫(yī)正骨,2015,27(09):44.
[13]赫軍,諸葛天諭,李冬冬,等.中藥內服聯合針刺與埋針法治療幼年強直性脊柱炎[J].中醫(yī)正骨,2016,28(01):41.
[14]赫軍,諸葛天諭,李冬冬,等.四聯療法治療強直性脊柱炎[J].中醫(yī)正骨,2016,28(06):50.
[15]張遂連,袁星星.自我管理在強直性脊柱炎患者門診護理中的應用[J].中醫(yī)正骨,2017,29(03):79.
[16]李現林,薛華珍,陳星,等.口服通痹舒筋丸治療強直性脊柱炎寒濕痹阻證[J].中醫(yī)正骨,2017,29(05):31.
[17]龔家川.影響強直性脊柱炎患者髖關節(jié)受累的危險因素分析[J].中醫(yī)正骨,2017,29(06):25.
　GONG Jiachuan.Analysis of risk factors for affection of hip joint in patients with ankylosing spondylitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(12):25.
[18]李洛宜,張依山,王笑青,等.系列化視頻在強直性脊柱炎健康教育中的應用[J].中醫(yī)正骨,2018,30(03):78.
[19]任偉凡,胡勁濤,全仁夫,等.強直性脊柱炎易感基因的相關研究進展[J].中醫(yī)正骨,2019,31(04):48.
[20]楊愛娟,徐保平,王曉濤.新風膠囊治療強直性脊柱炎臨床療效的系統(tǒng)評價[J].中醫(yī)正骨,2020,32(07):12.
　YANG Aijuan,XU Baoping,WANG Xiaotao.Clinical efficacy of Xinfeng(新風)capsule for treatment of ankylosing spondylitis:a systematic review[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2020,32(12):12.

備注/Memo

備注/Memo:
基金項目:浙江省科技計劃項目(2014C03031) 通訊作者:全仁夫 E-mail:[email protected]
更新日期/Last Update: 2018-05-02